Newtopia (NEWU) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined to CAD 1.6 million from CAD 2.4 million year-over-year, mainly due to client program changes and discontinuations.

• Gross profit margin was 48%, down from 50% in Q2 2023.

• Operating loss increased to CAD 727,000 from CAD 436,000 in Q2 2023.

• Company is pursuing growth through partnerships, GLP-1 drug integration, and health AI collaborations.

• Announced a strategic review process to explore alternatives such as a sale, merger, or strategic investment to maximize shareholder value and address indebtedness.

Financial highlights

• Q2 2024 revenue was CAD 1.6 million, down from CAD 2.4 million year-over-year.

• Gross profit was CAD 0.8 million, representing 48% of revenue.

• Selling, general, and administrative expenses improved by 15% year-over-year to CAD 1.1 million.

• Adjusted operating expenses (excluding share-based compensation) improved by 18% to CAD 1.5 million.

• Cash balance as of June 30, 2024, was CAD 0.52 million, with continued access to a revolving line of credit.

Outlook and guidance

• Actively reducing variable costs and accelerating new market opportunities to offset lost revenue.

• Management remains optimistic about strategic positioning in healthcare and aims to return to EBITDA positive through pipeline execution.

• Growth targeted via innovation partnerships, GLP-1 drug integration, and health AI collaborations.